Anna Gigli

Anna Gigli

Auto-generated profile, based on publicly available information

Anna Gigli

Institute for Research on Population and Social Policies, National Research Council, Rome, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
LMLuigino DAL MASO
Luigino DAL MASO
SGStefano Guzzinati
Stefano Guzzinati
CBC. Buzzoni
C. Buzzoni
RCR. Capocaccia
R. Capocaccia
DSDiego Serraino
Diego Serraino
RCR. Cusimano
R. Cusimano
Persons living after a cancer diagnosis represent 4% of the whole population in high-income countries. The aim of the study was to provide estimates of indicators of long-term survival and cure for 26 cancer types, presently lacking. Data on 818 902 Italian cancer patients diagnosed at age 15–74 years in 1985–2005 were included. Proportions of patients with the same death rates of the general population (cure fractions) and those of prevalent patients who were not at risk of dying as a result of cancer (cure prevalence) were calculated, using validated mixture cure models, by cancer type, sex, and age group. We also estimated complete prevalence, conditional relative survival (CRS), time to reach 5- and 10-year CRS >95%, and proportion of patients living longer than those thresholds. The cure fractions ranged from >90% for patients aged <45 years with thyroid and testis cancers to 95% were both reached in 95% after 19 and 25 years, respectively, and in 15 and 18 years for prostate cancer patients. Five-year CRS remained 25 years after cancer diagnosis in patients with liver and larynx cancers, non-Hodgkin lymphoma, myeloma, and leukaemia. Overall, the cure prevalence was 67% for men and 77% for women. Therefore, 21% of male and 31% of female patients had already reached 5-year CRS >95%, whereas 18% and 25% had reached 10-year CRS >95%. A quarter of Italian cancer patients can be considered cured. This observation has a high potential impact on health planning, clinical practice, and patients' perspective.

9 February 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SGStefano Guzzinati
Stefano Guzzinati
SVSaverio Virdone
Saverio Virdone
RARoberta De Angelis
Roberta De Angelis
CPChiara Panato
Chiara Panato
CBCarlotta Buzzoni
Carlotta Buzzoni
LMLuigino DAL MASO
Luigino DAL MASO
Background: Estimates of cancer prevalence are widely based on limited duration, often including patients living after a cancer diagnosis made in the previous 5 years and less frequently on complete prevalence (i.e., including all patients regardless of the time elapsed since diagnosis). This study aims to provide estimates of complete cancer prevalence in Italy by sex, age, and time since diagnosis for all cancers combined, and for selected cancer types. Projections were made up to 2020, overall and by time since diagnosis. Methods: Data were from 27 Italian population-based cancer registries, covering 32% of the Italian population, able to provide at least 7 years of registration as of December 2009 and follow-up of vital status as of December 2013. The data were used to compute the limited-duration prevalence, in order to estimate the complete prevalence by means of the COMPREV software. Results: In 2010, 2,637,975 persons were estimated to live in Italy after a cancer diagnosis, 1.2 million men and 1.4 million women, or 4.6% of the Italian population. A quarter of male prevalent cases had prostate cancer (n = 305,044), while 42% of prevalent women had breast cancer (n = 604,841). More than 1.5 million people (2.7% of Italians) were alive since 5 or more years after diagnosis and 20% since ≥15 years. It is projected that, in 2020 in Italy, there will be 3.6 million prevalent cancer cases (+ 37% vs 2010). The largest 10-year increases are foreseen for prostate (+ 85%) and for thyroid cancers (+ 79%), and for long-term survivors diagnosed since 20 or more years (+ 45%). Among the population aged ≥75 years, 22% will have had a previous cancer diagnosis. Conclusions: The number of persons living after a cancer diagnosis is estimated to rise of approximately 3% per year in Italy. The availability of detailed estimates and projections of the complete prevalence are intended to help the implementation of guidelines aimed to enhance the long-term follow-up of cancer survivors and to contribute their rehabilitation needs.

11 March 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SFSilvia Francisci
Silvia Francisci
SGStefano Guzzinati
Stefano Guzzinati
LMLuigino DAL MASO
Luigino DAL MASO
CSCarlotta Sacerdote
Carlotta Sacerdote
CBCarlotta Buzzoni
Carlotta Buzzoni
AGAIRTUM Working Group
AIRTUM Working Group

1 August 2013 in JNCI Monographs
Verified
Journal Article
Open access
PDF file
JLJoseph Lipscomb
Joseph Lipscomb
KYK. Robin Yabroff
K. Robin Yabroff
MHMark C. Hornbrook
Mark C. Hornbrook
AGAnna Gigli
Anna Gigli
SFSilvia Francisci
Silvia Francisci
AMAngela Mariotto
Angela Mariotto
This monograph highlights the multiple payoffs from comparing patterns of cancer care, costs, and outcomes across health systems, both within a single country or across countries, and at a point in time or over time. The focus of comparative studies can be on the relative performance of systems in delivering quality cancer care, in controlling the cost of cancer care, or in improving outcomes, such as reducing mortality rates and improving survival. The focus also can be on comparing the effectiveness, cost, or cost-effectiveness of competing cancer prevention and control interventions within a given system or across systems, while taking into account variations in patient characteristics, disease incidence and severity, resource availability, unit costs, and other factors influencing system performance.

5 July 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SFSilvia Francisci
Silvia Francisci
SGStefano Guzzinati
Stefano Guzzinati
MMMAURA MEZZETTI
MAURA MEZZETTI
Emanuele CrocettiEmanuele Crocetti
Emanuele Crocetti
FGFrancesco Giusti
Francesco Giusti
AGAnna Gigli
Anna Gigli
Background Due to changes in cancer-related risk factors, improvements in diagnostic procedures and treatments, and the aging of the population, in most developed countries cancer accounts for an increasing proportion of health care expenditures. The analysis of cancer-related costs is a topic of several economic and epidemiological studies and represents a research area of great interest to public health planners and policy makers. In Italy studies are limited either to some specific types of expenditures or to specific groups of cancer patients. Aim of the paper is to estimate the distribution of cancer survivors and associated health care expenditures according to a disease pathway which identifies three clinically relevant phases: initial (one year following diagnosis), continuing (between initial and final) and final (one year before death). Methods The methodology proposed is based on the reconstruction of patterns of care at individual level by combining different data sources, surveillance data and administrative data, in areas covered by cancer registration. Results A total colorectal cancer-related expenditure of 77.8 million Euros for 18012 patients (corresponding to about 4300 Euros per capita) is estimated in 2006 in two Italian areas located in Tuscany and Veneto regions, respectively. Cost of care varies according to the care pathway: 11% of patients were in the initial phase, and consumed 34% of total expenditure; patients in the final (6%) and in the continuing (83%) phase consumed 23% and 43% of the budget, respectively. There is an association between patterns of care/costs and patients characteristics such as stage and age at diagnosis. Conclusions This paper represents the first attempt to attribute health care expenditures in Italy to specific phases of disease, according to varying treatment approaches, surveillance strategies and management of relapses, palliative care. The association between stage at diagnosis, profile of therapies and costs supports the idea that primary prevention and early detection play an important role in a public health perspective. Results from this pilot study encourage the use of such analyses in a public health perspective, to increase understanding of patient outcomes and economic consequences of differences in policies related to cancer screening, treatment, and programs of care.

1 January 1995 in IEEE Transactions on Information Theory
Verified
Journal Article
Closed access
PBP. Barone
P. Barone
AGA. Gigli
A. Gigli
MPM. Piccioni
M. Piccioni
The determination of the asymptotically efficient importance sampling distribution for evaluating the tail probability P(Ln>u) for large n by Monte Carlo simulations, is considered. It is assumed that Ln is the likelihood ratio statistic for the optimal detection of signal with spectral density sˆ from noise with spectral density cˆ, Ln=(2n)-1Xnt{Tn (cˆ)-1ITn(cˆ+sˆ)-1 }Xn, cˆ and sˆ being both modeled as invertible Gaussian ARMA processes, and Xn being a vector of n consecutive samples from the noise process. By using large deviation techniques, a sufficient condition for the existence of an asymptotically efficient importance sampling ARMA process, whose coefficients are explicitly computed, is given. Moreover, it is proved that such an optimal process is unique